NVO stock: buy or sell?
November 15th, 2019
Novo Nordisk A\u002FS, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide.
Should I buy NVO stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, 2 buy setups are elegible for Novo Nordisk A/S stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Novo Nordisk A/S stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 11 ratings published for NVO stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-13||Bank of America||n/a||Neutral|
|2019-9-13||Bank of America||n/a||Neutral|
|2019-8-30||Jefferies Financial Group||Hold||Underperform|
|2019-4-29||Credit Suisse Group||Neutral||Outperform|
|2019-2-1||Morgan Stanley||n/a||Equal Weight|
NVO stock analysis
After topping to all time highs on November 14th, Novo Nordisk A/S depreciated -1.05% to $57.28.
After topping to all time highs on Nov/14, Novo Nordisk A/S depreciated -1.05% to $57.28. On October 3rd NVO price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock. Since last July when SMA50d and SMA100d crossed up, NVO price gained $9.29 per share (19.36%). On November 14th, NVO hit new all time highs, pushing higher previous ATH of $57.93 recorded on Nov 8th. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Novo Nordisk A/S shares set new all time highs back again this week, setting highs to $58.01. Shares closed at $57.28 and decreased -1.02% during the week. After 4 weeks soaring, this week declined a -1.04%.
In a weekly time frame, Novo Nordisk A/S stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, NVO might consolidate in a flat-base, waiting to break out over or down under . Since price and SMA40w lines crossed up by mid July, NVO climbed $10.16 (21.56%). Since SMA20d and SMA40w crossed up by mid March, NVO price climbed $8.78 per share (18.10%).
NVO stock price history
NVO IPO was on April 30th, 1981 at $0.00 per share1. Since then, NVO stock surged a inf%, with a yearly average of inf%. If you had invested $1,000 in NVO stock in 1981, it would worth $inf today.
1: Adjusted price after possible price splits or reverse-splits.
NVO stock historical price chart
NVO stock reached all-time highs on November/14 with a price of $58.01.
NVO stock price target is $300.90Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 4 price forecasts for Novo Nordisk A/S stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-13||Bank of America||Reiterates||$355.00||$400.00||12.7%|
|2019-9-13||Bank of America||Raises Target||$355.00||$400.00||12.7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareNovo Nordisk A/S disappointed analysts on February when it published an Earnings per Share (EPS) of $0.54 when the analysts' forecast was $0.57.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Novo Nordisk A/S annual sales remained constant a neutral 0.12% to $111,831.00 million dollars from $111,696.00 marked in 2017. Aligned with this, its earnings margin (compared to sales) stayed steady to 34.54%, that is $38,628.00 million.
|2013||$83,570 M||-||$25,180 M30.1%||-|
|2014||$14,427 M||-82.74%||$4,302 M29.8%||-82.92%|
|2015||$107,927 M||648.09%||$34,860 M32.3%||710.33%|
|2016||$111,780 M||3.57%||$37,925 M33.9%||8.79%|
|2017||$111,696 M||-0.08%||$38,130 M34.1%||0.54%|
|2018||$111,831 M||0.12%||$38,628 M34.5%||1.31%|
Quarterly financial resultsNovo Nordisk A/S reported $29,732.00 million in sales for 2018-Q4, a 7.10% up compared to previous quarter. Reported quarter earnings marked $8,497.00 M with a profit margin of 28.58%. Profit margin decreased a -3.97% compared to previous quarter when profit margin was 32.55%. When comparing turnover to same quarter last year, Novo Nordisk A/S sales marked an exceptional increase and boosted a 559.07%. Looking back to recent quarterly results, Novo Nordisk A/S posted 5 positive quarters in a row.
|2017-Q1||$28,450 M||-||$10,160 M35.7%||-|
|2017-Q2||$28,640 M||0.67%||$9,950 M34.7%||-2.07%|
|2017-Q3||$4,200 M||-85.34%||$1,542 M36.7%||-84.51%|
|2017-Q4||$4,511 M||7.42%||$1,330 M29.5%||-13.73%|
|2018-Q1||$26,930 M||496.96%||$10,751 M39.9%||708.32%|
|2018-Q2||$27,407 M||1.77%||$10,343 M37.7%||-3.79%|
|2018-Q3||$27,762 M||1.30%||$9,037 M32.6%||-12.63%|
|2018-Q4||$29,732 M||7.10%||$8,497 M28.6%||-5.98%|
Novo Nordisk A/S ownershipWhen you are planning to invest in a stock, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Novo Nordisk A/S, 0.02% of all outstanding shares are owned by its staff.
In case of Novo Nordisk A/S stock, 9.41% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVO stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$135.2 B||$95.5 B||$108.7 B||$206.2 B||$115.7 B|
|Total shares||2,360.0 M||1,630.0 M||960.1 M||5,530.0 M||2,510.0 M|
|Float shares||1,680.0 M||1,630.0 M||842.1 M||5,520.0 M||2,230.0 M|
|- Institutional holdings (%)||9.4%||75.0%||81.5%||76.2%||7.7%|
|- Insider holdings (%)||0.0%||0.1%||0.1%||0.0%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$57.25 - $57.75|
|Average true range||$0.89|
|50d mov avg||$53.16|
|100d mov avg||$51.60|
|200d mov avg||$50.29|
Novo Nordisk A/S performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Novo Nordisk A/S performance to Bristol-Myers Squibb, Eli Lilly and, Pfizer and :
|LLYEli Lilly and||3.00%||-1.32%||1.68%|
Novo Nordisk A/S competitorsOne check before trading any stock is to have a look a list of its competitors, in this case for Novo Nordisk A/S. We selected 4 companies as Novo Nordisk A/S competitors as they are in the same industry or have similar market objectives.
Latest NVO stock news
- Seeking AlphaNovo Nordisk's Oral Diabetes Drug Is A Force To Be Reckoned WithAugust 22, 2018
- Seeking AlphaNovo Nordisk: Obesity Crisis Continues To Get Worse - Buy The Stock TodayJune 3, 2018